Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

Ten adults with current major depressive disorder and borderline personality disorder will receive a single 25 mg oral dose of psilocybin in an open-label treatment study to evaluate safety and symptom change.

Primary hypothesis is that psilocybin will produce a significant reduction in MDD and BPD symptom scores at 1 week sustained to 4 weeks compared to baseline; outcomes include standard rating scales such as MADRS and BPD-SAS.